Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
Introduction. Coronavirus disease 2019 (COVID-19) can progress to severe respiratory compromise and lead to mortality due to induction of cytokine storm. Tocilizumab (TCZ) is approved by the FDA for the treatment of cytokine release syndrome (CRS). This study aims to analyze the outcomes among patie...
| Published in: | Advances in Virology |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2022/7060466 |